JP Patent

JP5812500B2 — 新規なβ３アドレナリン作動性受容体アゴニスト

Assigned to Merck and Co Inc · Expires 2015-11-17 · 11y expired

What this patent protects

Patent listed against vibegron.

Drugs covered by this patent

Patent Metadata

Patent number
JP5812500B2
Jurisdiction
JP
Classification
—
Expires
2015-11-17
Drug substance claim
No
Drug product claim
No
Assignee
Merck and Co Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.